AU2022214187A1 - Use of neuroactive steroids for treatment of sexual dysfunction - Google Patents
Use of neuroactive steroids for treatment of sexual dysfunction Download PDFInfo
- Publication number
- AU2022214187A1 AU2022214187A1 AU2022214187A AU2022214187A AU2022214187A1 AU 2022214187 A1 AU2022214187 A1 AU 2022214187A1 AU 2022214187 A AU2022214187 A AU 2022214187A AU 2022214187 A AU2022214187 A AU 2022214187A AU 2022214187 A1 AU2022214187 A1 AU 2022214187A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- administered
- acceptable salt
- sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142840P | 2021-01-28 | 2021-01-28 | |
| US202163142833P | 2021-01-28 | 2021-01-28 | |
| US63/142,833 | 2021-01-28 | ||
| US63/142,840 | 2021-01-28 | ||
| PCT/US2022/014075 WO2022165017A1 (en) | 2021-01-28 | 2022-01-27 | Use of neuroactive steroids for treatment of sexual dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022214187A1 true AU2022214187A1 (en) | 2023-07-13 |
| AU2022214187A9 AU2022214187A9 (en) | 2024-05-23 |
Family
ID=80787167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022214187A Pending AU2022214187A1 (en) | 2021-01-28 | 2022-01-27 | Use of neuroactive steroids for treatment of sexual dysfunction |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240122945A1 (https=) |
| EP (1) | EP4284382A1 (https=) |
| JP (1) | JP2024507638A (https=) |
| KR (1) | KR20230136599A (https=) |
| AU (1) | AU2022214187A1 (https=) |
| CA (1) | CA3206537A1 (https=) |
| IL (1) | IL304080A (https=) |
| MX (1) | MX2023008726A (https=) |
| WO (1) | WO2022165017A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| PE20240780A1 (es) * | 2021-07-28 | 2024-04-17 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801081A1 (ru) * | 2005-10-14 | 2008-10-30 | Х. Лундбекк А/С | Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP3068226A4 (en) * | 2013-11-11 | 2017-05-17 | Euthymics Bioscience, Inc. | Novel methods |
| ES2805598T3 (es) | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US20220125803A1 (en) * | 2019-03-04 | 2022-04-28 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
-
2022
- 2022-01-27 KR KR1020237025051A patent/KR20230136599A/ko active Pending
- 2022-01-27 AU AU2022214187A patent/AU2022214187A1/en active Pending
- 2022-01-27 CA CA3206537A patent/CA3206537A1/en active Pending
- 2022-01-27 US US18/263,189 patent/US20240122945A1/en active Pending
- 2022-01-27 WO PCT/US2022/014075 patent/WO2022165017A1/en not_active Ceased
- 2022-01-27 IL IL304080A patent/IL304080A/en unknown
- 2022-01-27 JP JP2023540524A patent/JP2024507638A/ja active Pending
- 2022-01-27 MX MX2023008726A patent/MX2023008726A/es unknown
- 2022-01-27 EP EP22704661.2A patent/EP4284382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507638A (ja) | 2024-02-21 |
| CA3206537A1 (en) | 2022-08-04 |
| IL304080A (en) | 2023-08-01 |
| MX2023008726A (es) | 2023-12-14 |
| KR20230136599A (ko) | 2023-09-26 |
| US20240122945A1 (en) | 2024-04-18 |
| AU2022214187A9 (en) | 2024-05-23 |
| EP4284382A1 (en) | 2023-12-06 |
| WO2022165017A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240122945A1 (en) | Use of neuroactive steroids for treatment of sexual dysfunction | |
| WO2022177718A1 (en) | Use of neuroactive steroid for treatment of sexual dysfunction | |
| US12409176B2 (en) | Methods of treating acute depression | |
| US8309535B2 (en) | Compositions and methods to treat recurrent medical conditions | |
| US20210077428A1 (en) | Bupropion as a modulator of drug activity | |
| CZ99597A3 (en) | Use of combination of tricyclic or tetracyclic antidepressant, inhibitor of serotonin recatching or inhibitor of monoaminooxidase with a compound inducing neurotransmitter or with a neurotransmitter precursor for preparing a medicament for treating or prevention of sclerosis multiplex or other demyelinisation states | |
| TWI638654B (zh) | 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物 | |
| CA3104811C (en) | Composition comprising pramipexole and nk1-antagonists for treating depression | |
| KR20230131927A (ko) | 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합 | |
| WO2012070043A1 (en) | Method and composition for weight-gain management | |
| JPH09501664A (ja) | 神経変性疾病におけるフルピルチンの一次及び二次神経保護作用 | |
| CN111973592A (zh) | 治疗肌萎缩侧索硬化和神经病的方法 | |
| CA2495452A1 (en) | Use of reboxetine for the treatment of hot flashes | |
| CZ301210B6 (cs) | Použití desoxypeganinu k ošetrování klinické deprese | |
| CN116847852A (zh) | 神经活性类固醇治疗性功能障碍的用途 | |
| US20140148465A1 (en) | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine | |
| TWI922961B (zh) | 用於治療抑鬱症之組合物及方法 | |
| HK40100385A (zh) | 用於神经精神病症的抗抑郁剂和右美沙芬的组合 | |
| CA2338330A1 (en) | Use of moclobemide for treating certain phsychiatric and medical disorders | |
| HK40060077A (en) | Domperidone compositions and methods for treating depression | |
| HK40034983A (en) | Treatment of post-traumatic syndrome disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SAGE THERAPEUTICS, LLC |